Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Entra ASA
OSE:ENTRA
|
NO |
Biodexa Pharmaceuticals PLC
Other
Biodexa Pharmaceuticals PLC
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Other
$1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Other
-£5.7m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-30%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Other
-£14.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Biodexa Pharmaceuticals PLC
Glance View
Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 27 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The firm is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.
